Pacritinib Citrate Patent Expiration
Pacritinib Citrate is Used for treating myelofibrosis by inhibiting Janus Associated Kinase 2 (JAK2). It was first introduced by Cti Biopharma Corp
Pacritinib Citrate Patents
Given below is the list of patents protecting Pacritinib Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vonjo | US8980873 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | Mar 25, 2030 | Cti Biopharma Corp |
| Vonjo | US8153632 | Oxygen linked pyrimidine derivatives | Jan 17, 2029 | Cti Biopharma Corp |
| Vonjo | US9573964 | Oxygen linked pyrimidine derivatives | May 05, 2028 | Cti Biopharma Corp |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pacritinib Citrate's patents.
Latest Legal Activities on Pacritinib Citrate's Patents
Given below is the list recent legal activities going on the following patents of Pacritinib Citrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9573964 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9573964 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US9573964 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9573964 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Aug, 2022 | US8980873 |
| Initial letter Re: PTE Application to regulating agency | 01 Jul, 2022 | US9573964 |
| Change in Power of Attorney (May Include Associate POA) Critical | 19 Jan, 2022 | US9573964 |
| Email Notification Critical | 19 Jan, 2022 | US9573964 |
| Email Notification Critical | 18 Jan, 2022 | US8980873 |
| Change in Power of Attorney (May Include Associate POA) Critical | 18 Jan, 2022 | US8980873 |
Pacritinib Citrate's Family Patents
